The following is a summary of “Calcitonin gene-related peptide in newly diagnosed idiopathic intracranial hypertension: a ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be ...

Despite its importance, problems related to CSF often go unnoticed until something goes wrong.

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Rapid diagnosis and treatment are critical in cases of ... For example, if you just need to check whether the patient has intracranial hypertension, 5 to 10 minutes of use may be enough," explains ...

This Idiopathic Intracranial Hypertension Treatment market research report offers invaluable insights into the industry’s current landscape, growth prospects, and future trends from 2025 to 2033.

Idiopathic intracranial hypertension is caused by a buildup ... Finally, your vision will begin to deteriorate if you don’t seek treatment in time. It’s important to see a doctor if you ...